Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T‐cell acute lymphoblastic leukaemia
British Journal of Haematology · 2025-04 · 206 (4) · 1165-1172
DOI: 10.1111/bjh.20007 ↗At a glance
Journal article in British Journal of Haematology, published online on 2025-02-24. Written by Chen Zhao and 14 co-authors. Institution: Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, National Clinical Research Center f…. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Transplantation, Haploidentical. Cited 3 times so far (Crossref); 55 references. Funded by: National Key Research and Development Program of China, Key Program of National Natural Science Foundation of China, Capital Health Development and Research of Special.
Abstract (original language)
The outcomes are poor for paediatric patients with T‐cell acute lymphoblastic leukaemia (T‐ALL) who relapse after haematopoietic stem cell transplantation (HSCT). However, studies focusing on paediatric patients with T‐ALL following haploidentical HSCT (haplo‐HSCT) are limited. We retrospectively identified a consecutive cohort comprising of 128 paediatric T‐ALL after haplo‐HSCT from 2642 consecutive ALL patients between January 2010 and June 2022. The 2‐year overall survival and leukaemia‐free survival were 67.77% ± 4.21% and 66.34% ± 3.82%, respectively, and the cumulative incidence of relapse (CIR) and non‐relapse mortality were 33.82% ± 0.70% and 12.65% ± 0.46% respectively. According to the multivariate Cox regression analysis, CD34 cells, minimal residual disease (MRD) ≥0.01% before HSCT, chronic graft‐versus‐host disease (cGvHD) and cytomegalovirus were associated with relapse ( p < 0.05). To develop a scoring system for stratifying patients, we combined the variables and stratified them into low (0–2 points) and high (3, 4) groups. Consequently, the 2‐year CIR in low and high groups were 23.76% ± 1.83% and 48.22% ± 2.42% ( p = 0.009), respectively. Children with T‐ALL have poor long‐term survival, and haplo‐HSCT is a potent and safe treatment; however, the incidence of relapse is high. Eliminating pre‐HSCT MRD, guaranteeing sufficient CD34 cells infusion and the occurrence of cGvHD and cytomegalovirus reactivation may benefit from relapse.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking Un…
ORCID profiles: Meng-Yu Xiao, Xiao-Hui Zhang
Funding
- National Key Research and Development Program of China
- Key Program of National Natural Science Foundation of China
- Capital Health Development and Research of Special
- Beijing Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Cite
APA
Zhao, C., Xiao, M. Y., Zhang, F., Bai, L., Hu, G. H., Suo, P., Wang, F. R., Wang, Z. D., Mo, X. D., Wang, Y., Zhang, Y. Y., Xu, L. P., Huang, X. J., Cheng, Y. F., & Zhang, X. H. (2025). Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T‐cell acute lymphoblastic leukaemia. British Journal of Haematology, 206(4), 1165-1172. https://doi.org/10.1111/bjh.20007
Vancouver
Zhao C, Xiao MY, Zhang F, Bai L, Hu GH, Suo P, et al. Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 2025;206(4):1165-1172. doi:10.1111/bjh.20007
BibTeX
@article{Zhao2025,
author = {Zhao, Chen and Xiao, Meng-Yu and Zhang, Feng and Bai, Lu and Hu, Guan-Hua and Suo, Pan and Wang, Feng-Rong and Wang, Zhi-Dong and Mo, Xiao-Dong and Wang, Yu and Zhang, Yuan-Yuan and Xu, Lan-Ping and Huang, Xiao-Jun and Cheng, Yi-Fei and Zhang, Xiao-Hui},
title = {Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T‐cell acute lymphoblastic leukaemia},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {4},
pages = {1165--1172},
doi = {10.1111/bjh.20007}
}
EUVIMED